Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Orchestra BioMed Holdings (OBIO) Change in Cash: 2022-2025

Historic Change in Cash for Orchestra BioMed Holdings (OBIO) over the last 4 years, with Sep 2025 value amounting to $23.3 million.

  • Orchestra BioMed Holdings' Change in Cash rose 1129.55% to $23.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $16.4 million, marking a year-over-year increase of 151.37%. This contributed to the annual value of -$8.3 million for FY2024, which is 177.01% down from last year.
  • Per Orchestra BioMed Holdings' latest filing, its Change in Cash stood at $23.3 million for Q3 2025, which was up 5,701.25% from $401,000 recorded in Q2 2025.
  • In the past 5 years, Orchestra BioMed Holdings' Change in Cash registered a high of $77.6 million during Q2 2022, and its lowest value of -$77.2 million during Q4 2022.
  • Moreover, its 3-year median value for Change in Cash was $389,000 (2024), whereas its average is $2.0 million.
  • In the last 5 years, Orchestra BioMed Holdings' Change in Cash slumped by 564.37% in 2024 and then surged by 1,129.55% in 2025.
  • Over the past 4 years, Orchestra BioMed Holdings' Change in Cash (Quarterly) stood at -$77.2 million in 2022, then soared by 114.87% to $11.5 million in 2023, then crashed by 129.13% to -$3.3 million in 2024, then skyrocketed by 1,129.55% to $23.3 million in 2025.
  • Its Change in Cash was $23.3 million in Q3 2025, compared to $401,000 in Q2 2025 and -$3.9 million in Q1 2025.